Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of NKTR-102 (PEG-irinotecan) Q14D vs Q21D in Metastatic Breast Cancer After Taxane Failure
2008-005577-36Phase 2Completed
- Sponsor
- Nektar Therapeutics
- Start
- Jan 2009
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label trial of etirinotecan pegol in breast cancer (2 arms), sponsored by Nektar Therapeutics. Primary endpoints: Objective Response Rate (Q14D schedule) and Objective Response Rate (Q21D schedule). Started Jan 2009; status: completed.
02
Drugs
etirinotecan pegol
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2008-005577-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005577-36.